GlassScriptPhysician profile
Erin Botti
NPI 1013244730
$8,332.02
in general payments reported to CMS, 2019-2025
34 companies · $3,345 in 2025
The $3,345 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $807 · 2023: $1,908 · 2024: $2,056 · 2025: $3,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,220 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,220.01 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.25 | 2022-2025 | |
| Janssen Biotech, INC. | $1,128.60 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $777.89 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $639.46 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $604.37 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $452.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $451.01 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $329.37 | 2021-2025 | Linzess |
| Ardelyx, INC. | $301.63 | 2022-2025 | Ibsrela |
| Exact Sciences Corporation | $221.28 | 2023-2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $205.90 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $196.21 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $177.47 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $171.54 | 2024-2025 | Voquezna |
| Celgene Corporation | $136.80 | 2022-2024 | Zeposia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Gilead Sciences, INC. | $107.44 | 2023-2025 | |
| Lilly USA, LLC | $98.03 | 2021-2025 | Omvoh |
| Braintree Laboratories, INC. | $84.66 | 2021-2023 | Sutab, Suflave |
| Cumberland Pharmaceuticals, INC. | $82.29 | 2023 | Kristalose |
| Vivus LLC | $73.61 | 2024-2025 | Pancreaze, Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.60 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $42.73 | 2024 | |
| Celltrion USA INC. | $39.68 | 2024 | Vegzelma |
| Redhill Biopharma INC. | $39.13 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Biohaven Pharmaceuticals, INC. | $36.53 | 2021 | |
| Merck Sharp & Dohme LLC | $36.41 | 2022 | |
| Ferring Pharmaceuticals INC. | $31.96 | 2024-2025 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $28.37 | 2021 | |
| Organon LLC | $25.13 | 2023 | Renflexis, Hadlima |
| Alnylam Pharmaceuticals INC. | $20.91 | 2024 | Givlaari |
| Novo Nordisk INC | $18.02 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $13.06 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Botti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.